Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers

Modern Pathology

Volumn 26, Issue 4, 2013, Pages 572-578

  Reitsma, Welmoed ^a   Mourits, Marian J E ^a   De Bock, Geertruida H ^a   Hollema, Harry ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

BRCA; endometrial cancer; pelvic high grade serous carcinoma; risk reducing salpingooophorectomy; serous endometrial intraepithelial carcinoma; uterine papillary serous carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BRCA2 GENE; CANCER INCIDENCE; CANCER RISK; CONFIDENCE INTERVAL; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PELVIC HIGH GRADE SEROUS CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; STANDARDIZED INCIDENCE RATIO; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PELVIC NEOPLASMS; SALPINGECTOMY;

EID: 84876493342     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.169     Document Type: Article

References (54)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics 2010) CA Cancer J Clin 2010;60:277-300.
2. Cho KR, Shih IeM. Ovarian cancer. Annu Rev Pathol 2009;4:287-313.
3. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-44. (Pubitemid 38018236)
4. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-2265. (Pubitemid 30246777)
5. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710. (Pubitemid 32203724)
6. Shaw PA, McLaughlin JR, Zweemer RP, et al. Histo-pathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002;21:407-411.
7. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518. (Pubitemid 38529752)
8. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-486. (Pubitemid 36432423)
9. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29:218-224. (Pubitemid 40170640)
10. Reitsma W, Hollema H, Mourits MJ. Letter commenting on 'Risk-Reducing Salpingo-Oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 2011;21:846-851; by C. Bethan Powell et al. Int J Gynecol Cancer '2011.
11. Jarboe E, Folkins A, Nucci MR, et al. Serous carcino-genesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008;27:1-9. (Pubitemid 351627965)
12. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-456. (Pubitemid 33069670)
13. Massuger L, Roelofsen T, Ham M, Bulten J. The origin of serous ovarian cancer may be found in the uterus: a novel hypothesis. Med Hypotheses 2010;74:859-861.
14. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopatholo-gic features. Am J Surg Pathol 1992;16:600-610.
15. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26:1260-1267.
16. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6: 93-108. (Pubitemid 12108965)
17. De Bock GH, Hesselink JW, Roorda C, et al. Model of care for women at increased risk of breast and ovarian cancer. Maturitas 2012;71:3-5.
18. The Netherlands Foundation for the Detection of Hereditary Tumours (STOET). Guideline for diagnosis and prevention. Available athttp://www.stoet. nl/uploads/richtlijnenboekje.pdf (viewed on 1 November 2011).
19. Oei AL, Massuger LF, Bulten J, et al. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 2006;94:814-819.
20. Hermsen BB, Olivier RI, Verheijen RH, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 2007;96:1335-1342. (Pubitemid 46685786)
21. van der Velde NM, Mourits MJ, Arts HJ, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 2009;124:919-923.
22. Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005;23:6890-6898.
23. Madalinska JB, van Beurden M, Bleiker EM, et al. The impact of hormone replacement therapy on menopau-sal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24:3576-3582. (Pubitemid 46630529)
24. Fakkert IE, Jansen L, Meijer K, et al. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy. Breast Cancer Res Treat 2011;129:157-164.
25. van Niekerk CC, Vooijs GP, Bulten J. Increased risk of concurrent primary malignancies in patients diagnosed with a primary malignant epithelial ovarian tumor. Mod Pathol 2007;20:384-388. (Pubitemid 46348338)
26. Hemminki K, Aaltonen L, Li X. Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma. Cancer 2003;97:2432-2439. (Pubitemid 36542482)
27. Byar D. Rates and standardization, In: Breslow NE, Day NE(eds). Statistical Methods in Cancer Research. Vol II, The Design and Analysis of Cohort Studies. p69, International Agency for Research on Cancer: Lyon, France, 1987.
28. Levine DA, Lin O, Barakat RR, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001;80:395-398. (Pubitemid 32207542)
29. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-1365. (Pubitemid 35154140)
30. Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst 1999; 91:1310-1316.
31. Beiner ME, Finch A, Rosen B, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10. (Pubitemid 46054134)
32. Bland AE, Calingaert B, Secord AA, et al. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol 2009;112: 150-154.
33. Lavie O, Ben-Arie A, Segev Y, et al. BRCA germline mutations in women with uterine serous carcinoma-still a debate. Int J Gynecol Cancer 2010;20:1531-1534.
34. Goshen R, Chu W, Elit L, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 2000;79:477-481.
35. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971;2:163.
36. Scully RE. Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynaecol Obstet 1995;49(Suppl):S9-S15.
37. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622. (Pubitemid 34755669)
38. Domchek SM, Friebel TM, Garber JE, et al. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat 2010;124: 195-203.
39. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo- oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 2011;21:846-851.
40. Meeuwissen PA, Seynaeve C, Brekelmans CT, et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005;97: 476-482. (Pubitemid 40614892)
41. Rhiem K, Foth D, Wappenschmidt B, et al. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 2011; 283:623-627.
42. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161-169. (Pubitemid 46175016)
43. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25:3985-3190.
44. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002;87:52-56. (Pubitemid 36027101)
45. Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol 2006;194:1702-1709. (Pubitemid 43766909)
46. Evans DG, Clayton R, Donnai P, Shenton A, Lalloo F. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet 2009;17:1381-1385.
47. Hirst JE, Gard GB, McIllroy K, Nevell D, Field M. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer 2009;19:826-829.
48. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012;226:421-426.
49. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35. (Pubitemid 46092026)
50. Roelofsen T, van Kempen LC, van der Laak JA, et al. concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion? Int J Gynecol Cancer 2012;22: 457-464.
51. Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carcinoma of the fallopian tube: a clinicopatholo-gical study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999;72: 367-379. (Pubitemid 29118195)
52. Piver MS. Prophylactic oophorectomy: reducing the US death rate from epithelial ovarian cancer. a continuing debate. Oncologist 1996;1:326-330.
53. Averette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. Cancer 1993;71:1629-1638. (Pubitemid 23056083)
54. Mourits MJ, De Hullu JA, Van Der Zee AG, Hollema H. Letter commenting on 'Pathologic finding in prophylactic oophorectomy specimens in high-risk women' (87:52-6) by Pamela Paley, et al. (fax: + 31-206-685-9607). Gynecol Oncol 2004;93:571. (Pubitemid 38507641)